THERAPY DOSSIER · th-fe73669b2a73

Inhaled hydrogen sulfide

Drug · H2S gasotransmitter (inhaled route); not a discrete ChEMBL drug; no clinical trial of the inhaled route identified

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: H2S gasotransmitter (inhaled route); not a discrete ChEMBL drug; no clinical trial of the inhaled route identified
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: H2S
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22089191 ↗2012Mixed findings

Inhaled hydrogen sulfide induces suspended animation, but does not alter the inflammatory response after blunt chest trauma.

RatOtherSprague-DawleyMaleInhalation100 ppm continuous flowStarted immediately after trauma

Model: Blunt chest trauma (blast wave) pulmonary contusion

Hydrogen sulfide lowered body temperature and activity and partially attenuated mediator release in lavage and in Kupffer and splenic cell supernatants, and abrogated the rise in alveolar macrophages at 48 h, but did not alter neutrophil counts or mononuclear cell responses, and showed no overall p…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…